TRIO and infection: The failure of TRIO VLPs to achieve significant protection from infection may reflect differences between the challenge models used or suggest that an effective vaccine targeting TRIO either needs to target multiple epitopes (to more closely match the polyclonal response elicited by Dragovic et al. [24]) or needs to elicit higher titer antibody responses (to more closely match the concentration of 13F-1 mAb used by Chuang et al. [26]).